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The problem
High prices keep innovative medicines out of reach for many patients across Europe, resulting in
growing inequalities in accessibility and standards of care. Budgetary pressures compel payers and
insurers to make increasingly difficult choices, at the expense of patients and investment in
innovation. Costly new therapies become available only for the lucky few—or for no one in those
countries that lack the purchasing power or are left out of manufacturers’ marketing strategies
altogether. With expensive combination therapies adding to the problem, the potential of scientific
and medical innovation remains underused, not least in hematology. By severely limiting the
uptake of novel gene and cell therapies, high prices are undercutting efforts to increase, personalize
and optimize treatment options for patients suffering from blood disorders.1
Causes
High prices result from a complex set of interrelated factors. Causes can roughly be divided into
three categories:
Business models
Manufacturers are primarily driven by the need to recoup the costs of research and
development—of products that eventually make it onto the market and of those that don’t—and
by a desire to offer substantial return on investment to investors. In a system that rewards patent
rights with market exclusivity and which obscures R&D costs, price-setting and profit levels,
bringing a profitable drug to market continues to be the main incentive, not the patient and public
interest.
Market access
The authorization of drugs for the European market is based exclusively on criteria of safety and
efficacy.As longas these are not supplementedbyaffordability, added-value andquality-of-life criteria,
profit-driven development will prevail over models that put the patient and public interest first.
Pricing and reimbursement
Decision-making by public payers and insurers is done at the national level, based on different
models and methodologies, rather than at the European level in a harmonized, concerted manner.
Similarly, price negotiations with pharmaceutical companies are conducted by national
governments and in secrecy, instead of collectively and transparently. This fragmentation has
negative consequences for overall price levels, (widely disparate) accessibility for patients, value for
(taxpayers’) money and the sustainability of health systems.
The challenge
The overall picture is one of imbalance between public and private interests all along the
research-to-market development chain.2 Too often, rewarding (commercial) innovation and
investors prevails over the need to ensure access and affordability for patients and health systems.
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Clearly, achieving a perfect balance between private and public
benefits is not an end in itself. Nor is the reduction of prices per se.
The common goal of all stakeholders, in our view, must be to
develop and agree on a set of principles and practices for fair
pricing, that is, pricing that offers a proper and socially
acceptable reward for developers and funders of innovation
while ensuring affordable access to the best possible treatments
for all patients across Europe.
Solutions
In light of the sizable challenges and the disparities across
countries, no single, one-size-fits-all solution is possible. A
number of elements can be identified however that will have to be
part of any model for ensuring fair pricing and affordable access
to innovative medicines:
Intergovernmental collaboration on procurement
and reimbursement
Although more a response to, than a solution for the
fundamental defects of existing pharmaceutical business models,
cooperation between national governments on the procurement
and reimbursement of the growing number of very expensive
medicines is a necessary first step. The Beneluxa Initiative on
Pharmaceutical Policy3 offers the best example of how such
cooperation can strengthen payers’ negotiation power in the face
of the secretive divide-and-conquer approach traditionally
adopted by pharmaceutical companies. Beneluxa has explored
joint price negotiations and, potentially more impactful, joint
horizon scanning. Its creation of the International Horizon
Scanning Initiative (IHSI) addresses the information asymmetry
between governments and companies and establishes an ‘early-
warning system,’ allowing payers to better anticipate the arrival
of expensive new medicines. By exchanging information and
coordinating their ‘willingness to pay,’ the participating countries
effectively form a united front that can make their collective red
lines, rather than the company’s demands, the starting point of
price negotiations.
Collaborative, harmonized Health Technology Assessment
(HTA) would be another meaningful step towards ensuring
access to the best possible medical care at the best possible price.
Joint EU-level clinical assessments as proposed by the European
Commission4 will increase efficiency and reduce cost by pooling
resources and expertise, streamlining regulatory processes and
providing uniform guidance for Member States’ pricing and
reimbursement decisions.
New economic models
While increased cooperation is essential, more fundamental
change is needed. The case for developing a new economic model
for pharmaceuticals—one that is transparent, balances the
interests of all stakeholders and puts patients at the center—
has been made by EHA previously.5
In our view, the following principles should underlie any new
model for the development, marketing, pricing and reimburse-
ment of pharmaceuticals:
a) The whole decision-making chain from drug development to
pricing and reimbursement should be patient-centric, rather
than drug-centric. Patients must be (meaningfully) involved
throughout.
b) New medicines entering the European market should not only
be safe and efficacious (the criteria for authorization by the
European Medicines Agency, EMA); they must also be
affordable and accessible for patients and public health
systems.
c) In addition to safety, efficacy, affordability and accessibility,
relevant clinical and patient benefit should be a key factor in
pricing and reimbursement decisions. No public resources
should be wasted on medicines that offer little or no added
value compared to treatments already available. It is therefore
important to enhance the ability of health systems “to review
and adjust prices, and to withdraw funding for superseded or
less cost-effective medicines if required,” as suggested in a
WHO report on the pricing of cancer medicines.6 The
importance, as well as the complexity and the challenging
nature of increasing the value of pharmaceutical spending has
been aptly described by the OECD.7
d) Any form of pricing coordination at the European level will
have to take into account the differences in purchasing power
between countries. A ‘one size fits all’ solution will not be
possible.
e) Transparency is a pre-condition for developing any effective
and broadly accepted approach to ‘fair pricing.’ Manufac-
turers invoking costs to justify extraordinarily high pricing of
their products cannot leave patients and (tax)payers in the
dark about investment and profit levels. More openness from
industry on bench-to-market costs needs to be matched by
transparency from payers on the cost-benefit considerations
underlying pricing and reimbursement decisions. An interest-
ing model has been proposed by the International Association
of Mutual Benefit Societies (AIM), in which a fixed amount of
R&D costs for each new drug is used as the basis for
calculating fair prices. If a pharmaceutical company wants to
charge a higher price, it will have to provide full transparency
on cost.8
In an ideal scenario, the existing EU framework for market
approval would be complemented by a mechanism for joint HTA
(EU-level clinical assessments) as well as structural EU-level
coordination on pricing. Along the lines of themodel proposed by
Uyl and Löwenberg,9 such a mechanism would combine respect
for national price-setting competencies with a collective, multi-
stakeholder process for determining an upper limit to the price of
a new innovative drug. All collectively determined maximum
prices will have to be transparent, realistic and fair. Pricing
deliberations will have to take into account the clinical-scientific
evaluation of a treatment, the pharmaceutical industry’s data and
interests, and affordability for patients and health systems.
With innovative drugs becoming ever more costly, societal
willingness to pay for health gains, relative to disease burden
and budgetary impact, becomes an important factor—see
Annemans’s commendable concept of ‘VIA pricing’ (value-
informed, affordable prices for innovative medicines).10
Thus, in addition to safety, efficacy and cost-effectiveness,
socially and economically acceptable pricing must be a pre-
condition for reimbursement.
Incentivize affordable, accessible, sustainable
innovation
Since the causes of high prices are diverse and complex, no
single measure or model will suffice to push pricing levels down.
Intensified collaboration at the EU/international level and the
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introduction of new economic models will have to be
supplemented by a balanced set of incentives to keep innovation
affordable and accessible for patients and health systems.
Active encouragement—which can take the shape of financial
incentives, regulation or awareness campaigns—is needed in
particular to:
 spur innovations in the diagnosis and treatment of rare diseases
(see the EHA position paper on affordable access to orphan
medicinal products11).
 ensure affordable and equitable access to novel cell and gene
therapies, such as CAR T-cell therapy. These innovative
treatments represent a major step forward in personalized
medicine, however the high cost of developing and administer-
ing them, combined with the lack of a harmonized European
approach to clinical trials, regulatory approvals, HTA and
reimbursement, has slowed down their uptake and is keeping
them out of reach of the majority of European patients.
 increase access to publicly funded, cheaper clinical trials that
are investigator-driven,patient-centered, risk-based, and less
bureaucratic. In addition, development of practice-oriented
‘real-world trials’ may contribute to the optimization and
personalization of treatments, and thus to ensuring that scarce
healthcare budgets are spent on therapies that are cost-effective
and of real added value to patients.
 boost the uptake of biosimilars, which are as safe and
efficacious as their reference products but tend to be
considerably less expensive. By helping to drive down the
prices of the reference biologics themselves, as well as across
product classes, the overall pricing impact of biosimilars is
significant and likely to increase.12,13
 establish public-private partnerships that deliver affordable
innovation, respond to unmet clinical needs and ensure that the
interests of both public and private investors are served.
We would also incentivize, rather than enforce, transparency
on costs and price-setting. While we are a strong proponent of
transparency, it should not be imposed as a stand-alone measure.
Forced openness on pricing and cost could actually have a reverse
effect on access and affordability, especially in middle- and lower-
income countries, as Chalkidou et al have argued in response to
the WHO report on cancer pricing.14 The dilemmas around price
transparency, as articulated by the OECD,15 seem impossible to
resolve without a fundamental overhaul and EU-wide harmoni-
zation of how pricing and reimbursement decisions are made.
Conclusion
High prices are a serious impediment to the uptake of
innovative treatments and the sustainability of health systems.
They are by no means the only factor influencing availability and
accessibility, and it is important to stress that we do not regard the
reduction of high medicine prices as an end in itself. Affordability
is however crucial for improving access to the best possible
treatment for patients across Europe, which must be the primary
goal for healthcare professionals, the pharmaceutical industry
and public health systems.
The problem of (excessively) high prices has many causes and
can only be solved through a combination of targeted policies,
regulatory measures and collaboration between stakeholders. A
holistic approach is needed, which takes the whole product
lifecycle into account from development to uptake—with the
patient interest at the center at all times.
While much can be done at the national and regional level,
achieving real and lasting results is only possible through
collaboration at the European level. An EU policy and regulatory
framework for HTA, pricing and reimbursement is needed.
Where that is not (yet) possible, voluntary collaboration and
coordination between EU Member States needs to be strongly
encouraged. The EU and national authorities must heed the calls
for collaborative action from patients, healthcare professionals
and payers to ensure affordable and equal access to innovative
medicines across Europe.
Key messages for policy makers and
stakeholders
Affordability is crucial for improving access to innovative
treatments for patients across Europe, and must be the
primary goal for healthcare professionals, the pharmaceu-
tical industry and public health systems. Fair pricing
solutions must be developed by and with all stakeholders,
in a way that benefits both public and private stakeholders,
and with the patient’s interest at the center, at all times.
EHA calls on EUMember States to step up collaboration
and coordination on HTA, horizon scanning, price
negotiations and reimbursement.
EHA calls on the EU institutions to develop a
pharmaceutical strategy that:
 enables and supports collaboration between national
authorities on pricing and reimbursement with a
dedicated EU policy and regulatory framework
 prioritizes structural frameworks for harmonized HTA
and coordination on pricing
 takes a holistic lifecycle approach, supplementing the
safety and efficacy criteria at the heart of EU market
authorization with affordability, accessibility, cost-effec-
tiveness and (clinical/patient) benefit as requirements for
reimbursement
 offers a balanced set of incentives to keep innovation
affordable and accessible for patients and health systems
 promotes a new economic model for the development,
marketing, pricing and reimbursement of pharmaceuti-
cals that puts the patient at the center, balances the
interests of public and private stakeholders and takes into
account the differences in purchasing power between
countries (no one-size-fits-all).
EHA calls on all stakeholders to develop and agree on a
set of principles and practices for fair pricing, ie, pricing that
offers a proper and socially acceptable reward for
developers and funders of innovation while ensuring
affordable access to the best possible treatments for all
patients across Europe.
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